Added to YB: 2026-04-24
Pitch date: 2026-02-22
PRPO [bullish]
Precipio, Inc.
+6%
current return
Author Info
No bio for this author
Company Info
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Market Cap
$47.4M
Pitch Price
$25.50
Price Target
46.00 (+64%)
Dividend
N/A
EV/EBITDA
91.16
P/E
-117.51
EV/Sales
2.01
Sector
Health Care Providers and Services
Category
turnaround
Precipio, Inc. - $PRPO
PRPO: Specialty cancer diagnostics reached cash flow+ & adj EBITDA+ in Q3'25 on $6.8M rev (+30% YoY). Dual model: pathology services (46% GM→50% by mid-26 via operating leverage) + HemeScreen reagents (high-margin recurring). FY25 est $24.5M rev, FY26 $30.6M (+25%). MolDx approval unlocked Medicare (50% of patients). Repaid $1.1M debt w/ internal cash, zero equity raises planned. 2M FD shares, $47.8M EV = 1.6x sales vs 3x peer avg. Re-rating to 3x → $46/share (~2x). Risks: sales hiccup, distributor execution, LDT regs.
Read full article (6 min)